Introduction
Cerebral Oximetry, which is based on near-infrared spectroscopy (NIRS) technology, is an optical technique that allows for noninvasive and continuous monitoring of brain oxygenation by determining cerebral tissue blood oxygen saturation (SctO 2 ). Many research and observational studies were performed with neonates using various types of NIRS/cerebral oximetry monitors. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, no food and drug administration (FDA) approved cerebral oximeter is available for neonates. Successful validation of cerebral oximetry for the FDA has been done in human adult volunteer studies under protocols were jugular bulb and arterial blood samples were obtained under different levels of fractional inspired oxygen (FiO 2 ) levels. [16] [17] [18] [19] However, this type of cerebral oximetry validation study for neonates would be too high of risk and unethical. Finding the appropriate neonatal clinical study that allows access to brain venous blood without altering clinical care procedures is difficult. As a result, validating a cerebral oximeter monitor for neonate applications is a major challenge.
The aim of this study was to validate the noninvasive cerebral oximetry measurements. Cerebral venous oxygen saturation (SvO 2 ) measured from blood drawn from the cephalad catheter in neonates undergoing veno-venous (VV) extracorporeal membrane oxygenation (ECMO) was compared to the saturations measured using a prototype neonatal cerebral oximeter developed by CAS Medical Systems (FORE-SIGHTt, Branford, CT, USA, www.casmed.com). This study follows a protocol similar to a preliminary validation study of the CAS neonatal cerebral oximeter. 20 Neonatal patients undergoing VV-ECMO with cephalad catheterization offer a unique opportunity to validate cerebral oximetry by allowing access to cerebral venous blood via catheterization of proximal internal jugular vein.
ECMO background
Extracorporeal membrane oxygenation (ECMO) is defined as the use of a modified heart-lung machine combined with a membrane oxygenator to provide cardiopulmonary support for patients with reversible pulmonary and/or cardiac failure in whom maximal conventional therapies have failed. Most causes of neonatal respiratory failure are self-limited and ECMO allows time for the lung to recover from the underlying disease process and for reversal of pulmonary hypertension, which frequently accompanies respiratory failure in the newborn.
At the initiation of extracorporeal life support, a decision is first made as to whether the infant would best be served with VV or venoarterial (VA) support. More than 60% of neonatal ECMO patients reported in the Extracorporeal Life Support Organization (ELSO) registry have received treatment with VA bypass. 21 In neonates with respiratory failure, VA ECMO is gradually being replaced by a VV technique, which uses a single double-lumen catheter. The catheter is placed in the right atrium, where blood is drained and reinfused into the same chamber, thus requiring cannulation of only the right jugular vein, sparing the carotid artery. Other advantages of VV ECMO include maintenance of normal pulsatile blood flow and the theoretical advantage that particles entering the ECMO circuit enter by way of the pulmonary rather than the systemic circulation. The design of the original VV catheter resulted in significant recirculation, limiting its use when ECMO flows >350 ml/min were required. Research by Rais-Bahrami et al. resulted in development of a new catheter design which significantly lowers the degree of recirculation. 22 This catheter design in 12, 15, and 18 Fr. sizes allows the use of VV ECMO in a greater number of infants. 23 In VV-ECMO the proximal end of internal jugular vein is also cannulated for cephalad drainage. This catheter is placed at the jugular bulb to augment cerebral venous outflow. The jugular bulb catheter is connected to the venous tubing of the ECMO circuit via a luer connector with a three-way stopcock to facilitate blood sampling for cephalic venous saturation measurement. 24 This catheter allows access for brain venous blood needed to validate neonatal cerebral oximetry in a routine clinical setting.
Cerebral oximetry background
Cerebral oximetry is based on NIRS techniques where light is emitted at one point and sensed by a detector at a second point after passage through a medium such as biological tissue. 25 A cerebral oximetry sensor is placed on the forehead, and if there is adequate space, off to one side of the forehead to monitor one brain hemisphere as shown in Figure 1a . Bilateral left and right forehead sensors could also be used if collateral flow in the brain hemispheres is a concern. 8 In healthy subjects, bilateral sensor measurements are similar. 18, 19 Light from the sensor passes through the scalp and skull to interrogate primarily the gray matter of brain tissue as shown in Figure 1b . As a result of the high light scattering properties of biological tissue, a small amount of light reaches the sensor detector and can be used for spectroscopic analysis. Interrogation depth of the sensor is estimated to be ½ of light source to detector separation distance. 26 Interrogation depth into the brain also depends on scalp and skull thickness which must be subtracted from the sensor's overall interrogation depth. The sensor of the prototype CAS cerebral oximeter used in this study has a light source to detector separation of 25 mm. For example, for a 1-month-old infant that has an estimated scalp thickness of 3 mm 27 and a skull thickness of 4 mm, 28-30 the resultant estimated brain tissue interrogation depth for the CAS sensor is about 6 mm.
Like pulse oximetry, cerebral oximetry uses near-infrared light at different wavelengths to distinguish oxy-hemoglobin (HbO 2 ) and deoxy-hemoglobin (Hb) to quantify blood oxygenation in tissue based on spectroscopy techniques. This is possible because Hb and HbO 2 greatly absorb near-infrared light compared to other biological components and that Hb and HbO 2 have different light absorption spectras. The prototype CAS neonatal cerebral oximeter used in this study is a continuous wave NIRS system that uses a three wavelength laser light source (780, 804 and 850 nm) to resolve HbO 2 and Hb. SctO 2 is determined from the ratio of HbO 2 / (HbO 2 þ Hb). Light from the sensor interrogates blood in the microvasculature (i.e., arterioles, venules and capillaries), 31 with the contribution of venous to arterial blood volume at approximately 70-30% ratio. 20, 32 Therefore cerebral tissue blood oxygen saturation values are usually below arterial oxygen saturation (i.e. (SaO 2 ) or pulse oximeter arterial oxygen saturation (SpO 2 )) values and above brain venous oxygen saturation (i.e., cephalad catheter internal jugular oxygen saturation (SjvO 2 )) values. Unlike pulse oximetry, cerebral oximetry does not need pulsatile flow to make a measurement. Therefore cerebral oximetry offers a means to monitor brain blood oxygenation during circulatory arrest or cardiopulmonary bypass utilizing non pulsatile flow, whereas a pulse oximeter is non functional. When used as a standalone monitor, the cerebral oximeter displays SctO 2 . When used in conjunction with pulse oximetry, cerebral oximetry offers a promising method to determine noninvasively SvO 2 representative of cephalad or jugular bulb oxygen saturation under many physiological states when peripheral pulse oximetry SpO 2 is representative of brain SaO 2 and the venous to arterial blood volume ratio of 70% to 30% as described previously holds true. 18, 20 Other features of the CAS cerebral monitor include automatic shutdown of the sensor light source in case the sensor becomes dislodged from the patient, with an alarm to alert the user. Besides being a noninvasive monitor, cerebral oximetry does not need to be periodically recalibrated with cerebral venous blood samples, unlike the on-line catheter monitoring systems and jugular bulb oximetry monitors.
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Methods
Validation procedure
This study was approved by the Institutional Review Board (IRB) at Children's National Medical Center (CNMC). After obtaining parental informed consent, neonates routinely undergoing VV-ECMO with cephalad catheterization were enrolled in this study. The cerebral oximeter sensor was affixed on the neonate's forehead ( Figure 1a ) with a custom made adhesive pad and further secured by a Hypafix tape (BSN Medical GmbH & Co. Hamburg, Germany). A laptop computer displayed and stored data every 3 s from the cerebral oximeter along with pulse oximetry SpO 2 data (N595 Tyco/Nellcor, Pleasanton, CA, USA). Cephalad blood samples were periodically obtained and analyzed by the i-STAT (Abbott Point of Care, East Windsor, NJ, USA) and the IL-682 Co-oximeter (Instrumentation Laboratory, Lexington, MA, USA) to obtain SjvO 2 used to validate the monitor's accuracy. The IL-682 co-oximeter is used as a blood oximetry gold standard based on it's high accuracy of measuring oxygen saturation (%O 2 Hb accuracy: bias and precision 1±0.5%, IL-682 Product Specification). The time of each cephalad blood sample draw was recorded from the cerebral oximeter monitor clock for synchronization and matched to the corresponding cerebral oximetry SctO 2 , SvO 2 and pulse oximetry SpO 2 values for statistical analysis. The first objective of this study was to validate cerebral tissue saturation (SctO 2 ) measured by the CAS monitor with weighted values of SjvO 2 obtained from the cephalad catheter and pulse oximetry SpO 2 to calculate a co-oximetry Reference SctO 2 based on the following relationship using a venous to arterial blood volume ratio of 70-30%: [18] [19] [20] Reference SctO 2 ¼ ð0:7ÂSjvO 2 þ 0:3ÂSpO 2 
Þ ð1Þ
The second objective was to validate the derived noninvasive cerebral venous saturation (SvO 2 ) from combining cerebral oximetry SctO 2 with pulse oximetry SpO 2 of Equation (2) The data are presented in scatter plot form for linear regression analysis with determined Bias and Precision (1 s.d.) comparing cerebral oximetry SctO 2 to the Reference SctO 2 (from Equation (1)), and cerebral oximetry SvO 2 (from Equation (2)) to cephalad SjvO 2 to determine the accuracy of the monitor for SctO 2 and SvO 2 .
As it is expected that unequal number of data value pairs would be obtained from each subject, correlated data linear regression techniques were used to determine the linear regression relationship and correlation coefficient. 36 
Results
Our results from 17 neonates studied over a three year period demonstrated that SctO 2 and SvO 2 measured by the prototype cerebral oximeter showed a high level of agreement with the measured cephalad SvO 2 values. For subjects 1-7, the i-STAT was used to obtain SjvO 2 values and for subjects 8-17, the IL-682 co-oximeter was used to obtain SjvO 2 values. An example of data collected during this study is presented as tracing of raw data in Figure 2 . This figure shows two IL-682 co-oximetry measurements of SjvO 2 and the calculated Reference SctO 2 represented by the triangle and square data points respectively, along with the cerebral oximetry SctO 2 and derived SvO 2 measurements. Cerebral oximetry and pulse oximetry values were temporally matched to the co-oximetry data at the time the blood samples were drawn to form the respective SctO 2 and SvO 2 data sets to generate the scatter plots shown in Figures 3 and 4 . Scatter plots of SctO 2 vs reference SctO 2 (from Equation (1)) are shown in Figure 3 Regression equations were shown in Figures 3 and 4 , but do not provide overly meaningful information due to the limited range of oxygen saturation values measured from the subjects. The limited range of oxygen saturation values are inherent in a study like this because care of the patient is paramount, with blood samples randomly drawn during times when the subject was clinically stable. To show how the cerebral oximeter responds to drops in arterial oxygenation, an anecdotal desaturation event is shown in Figure 5 where SctO 2 and SvO 2 along with pulse oximetry SpO 2 decreased about 25-30%.
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Direct comparison of the cerebral blood saturations measured by i-Stat method vs the IL-682 co-oximeter, revealed that the correlation between the two commonly used blood analyzers were poor for 10 blood sample pairs ( Figure 6 ) where the bias and precision was 9.5±6.0%. Therefore, for subjects 8-17, cephald blood samples were analyzed by the IL-682 to obtain SjvO 2 .
Demographic information: 17 neonate subjects were studied, nine males and eight females, with weights ranging from 2.5 to 4.7 kg. Race breakdown: five subjects were Caucasian, six subjects were Hispanic and 6 subjects were African American. Diagnosis: nine subjects had meconium aspiration syndrome, seven subjects had primary pulmonary hypertension, and one subject had total anomalus pulmonary venous return. For the 17 subjects, the prototype CAS cerebral oximeter collected 1718 h (i.e. 71.6 days) of data, ranging from 24 to 218 h per subject. Two hundred and twenty-five blood samples were drawn from the cephalad catheter for co-oximetry analysis, ranging from five to 28 samples per subject.
Discussion
While NIRS technology based monitors have become a useful research tool for monitoring the brain, their clinical application has been hampered by accuracy, reliability and clinical interpretation of the measurements. One concern regarding accuracy of adult cerebral oximetry is the issue of signal contamination by the extracranial tissue layers. Compared to adults, neonates have a much thinner skull and scalp thickness, 18, 19 The neonate version of the CAS cerebral oximeter used in this study demonstrated a precision (1 s.d.) of ±5.1% (i.e., five digits) for SctO 2 , and ±7.3% for SvO 2 . The accuracy of noninvasive SvO 2 is lower than the accuracy of SctO 2 because potential errors from both SctO 2 and SpO 2 affect the measurements. The lower accuracy of cerebral oximetry in neonate applications could be attributable to an immature neonatal cerebral circulatory system, resulting in a more variable venous to arterial blood volume ratio from the average 70:30 used to validate cerebral oximetry. Other possibilities include increased contamination of cephalad brain venous blood with extracerebral tissues, possibly due to the small vessel diameters in relation to the sampling catheter which could result in non-ideal placement of the catheter. While cerebral Validation of a noninvasive neonatal optical cerebral oximeter K Rais-Bahrami et al oximetry accuracy is poorer than that pulse oximetry, the normal range for cerebral oximetry values is much greater, thus errors in cerebral oximetry accuracy are not clinically significant. For example, adult cerebral oximeter and jugular bulb measurements of SvO 2 was found to vary 15% for healthy subjects breathing room air, 18, 19 while pulse oximetry SpO 2 typically range from 95-100%. Validation of cerebral oximetry on neonates cannot ethically be done in similar controlled conditions as adults, so the next best clinical scenario is to validate the monitor during clinical procedures where brain venous blood is accessible, such as in VV-ECMO. A disadvantage of validation under noncontrolled conditions is that brain tissue oxygenation cannot be altered to obtain a full range of oxygenation changes. Therefore, for VV-ECMO subjects, reference co-oximetry measurements from blood samples were done at intervals of several hours based on clinical protocols during long term cerebral oximetry monitoring sessions. Several high temporal resolution desaturation events were observed where the prototype cerebral oximeter and pulse oximeter trended together. An example is presented in Figure 5 . This cohesive trending pattern further confirms the cerebral oximeter's performance during changes in brain oxygenation.
SctO 2 is a relativity new parameter. Lack of experience in the use of the parameter can therefore confuse the clinical interpretation of the measurements. SctO 2 values are below SaO 2 and above venous oxygen saturation values because of the mixed arterial-venous blood in the microvasculature. Clinicians are familiar with measuring the arterial to venous oxygen saturation difference to infer oxygen consumption in tissue. However, obtaining cerebral venous blood oxygen saturation is difficult because of its invasive nature. Therefore, cephalad or jugular bulb catheters for co-oximetry analysis is often utilized only in critically ill patients. Cerebral oxygenation status is then evaluated indirectly for most patients by peripheral blood oxygenation measurements from arterial blood co-oximetry and pulse oximetry monitoring. However, peripheral blood oxygenation monitoring does not guarantee that the brain is adequately oxygenated.
SctO 2 offers the capability to monitor direct brain tissue blood oxygen saturation noninvasively. One major advantage of cerebral oximetry is that SctO 2 measurements are not affected by impeded cerebral circulation, circulatory arrest or nonpulsatile flow. As blood flow is stagnant, circulatory arrest disrupts reliable pulse oximetry monitoring, as well as cephalad, jugular bulb oximety and arterial blood gas measurements. During circulatory arrest, cerebral oximetry SctO 2 will decrease as oxygen is being metabolized by brain tissue (our unpublished observations). 8, 9 SctO 2 is much more sensitive to brain oxygenation compared to pulse oximetry. For neonates, pulse oximetry SpO 2 readings typically vary from 85 to 100%. Even when SpO 2 is high (95-100%), SctO 2 can vary from 30 to 100%. This fluctuation is dependant on oxygen supply and demand, which can be affected by cerebral metabolism, hypercapnia, hypocapnia, hypothermia or other physiological conditions. SvO 2 is a cerebral oximetry parameter derived from SctO 2 and pulse oximetry SpO 2 by reversing the 70:30 venous to SaO 2 relationship (Equations (1 and 2)) used to verify SctO 2 . Cerebral oximetry SvO 2 measurements are valid provided that the cerebral circulation is intact and that pulse oximetry SpO 2 represents the SaO 2 input to the brain. Cerebral circulatory arrest or impediment by carotid artery blockage disrupts this relationship, making cerebral oximetry SvO 2 measurements not possible. Also, poor pulse oximetry measurements, impeded by poor peripheral circulation, can also disrupt SvO 2 measurements. For ECMO patients, cerebral circulation is intact, so cerebral oximetry SvO 2 monitoring can be done when cephalad catheters are not used, especially in the case of VA-ECMO.
To our knowledge, this is the first clinical trial in neonates to evaluate and validate the noninvasive optical cerebral oximeter in VV ECMO patients with direct access to a cephalad catheter for measurement of SvO 2 . In our clinical practice, our goal is to maintain a cephalad SjvO 2 X60% for our VV-ECMO patients. Using the CAS neonatal cerebral oximeter, our goal is to also maintain SvO 2 X60%. If the cephalad SjvO 2 is 60% and SpO 2 from pulse oximetry is 93%, the target cerebral oximetry SctO 2 would be X70% by use of Equation (1). Our institution is one of the few ECMO centers that use the cephalad catheter to monitor brain oxygenation. Since most VV-ECMO and VA-ECMO procedures do not use cephalad catheters, cerebral oximetry offers an alternative, noninvasive means to monitor brain oxygenation.
There has been renewed interest in NIRS type monitors, such as cerebral oximetry, as an easy to use, noninvasive technique for Validation of a noninvasive neonatal optical cerebral oximeter K Rais-Bahrami et al measuring tissue oxygenation in the brain. Recent technical advances have led to the development of compact, portable instruments that detect changes in optical attenuation of several wavelengths of light. NIRS is an evolving technology that holds significant potential for technical advancement. In particular, NIRS shows future promise as a clinical tool for bedside cerebral blood flow measurements and as a cerebral imaging modality for mapping structure and function.
Conclusion
The cerebral oximeter measurements agree well with the measured cerebral venous saturation. This noninvasive method of measuring cerebral tissue and venous saturation could easily be recommended as a substitute for drawing venous blood samples in order to measure cerebral venous saturations in neonates requiring extracorporeal life support. The blood sample measurements to verify and/or validate cerebral oximeters should preferably be done by standard co-oximeter such as the IL-682 and not by the i-Stat method.
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